Passage Bio Inc Sustainability Reports
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for rare monogenic central nervous system (CNS) disorders. The company focuses on utilizing adeno-associated virus (AAV) delivered therapeutics to treat diseases with significant unmet medical need.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
5 reports from 2020 to 2025
Company Profile
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing therapies for rare monogenic central nervous system (CNS) disorders. The company focuses on utilizing adeno-associated virus (AAV) delivered therapeutics to treat diseases with significant unmet medical need.
Reports
5 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
